The diagnostic test, developed by Biodesix, Inc, will help guide treatment decisions in patients with advanced lung cancer.
Biodesix, Inc, today announced that its VeriStrat test received a positive coverage decision from UnitedHealthcare, one of the largest commercial insurance companies in the US, with a published 44.7 million covered lives. In its Medical Policy, UnitedHealthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung cancer (NSCLC).”
VeriStrat, included in the standard of care guidelines, is a blood-based proteomic test that provides physicians with prognostic and predictive information that helps guide treatment of advanced NSCLC. Patients with a VeriStrat Poor test result have a shorter median overall survival than those with a VeriStrat Good result. Understanding the patient’s disease state can help inform physicians’ decisions on chemotherapy, palliative care or clinical trials.
Read the complete news release on Yahoo!: http://yhoo.it/1HcbqFK
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen